Raghav Sundar and Samuel Klempner
Aug 23, 2025, 17:06
Raghav Sundar: New Horizons for Claudin18.2 in GI Cancers
Raghav Sundar, Senior Consultant and Principal Investigator in cancer research at National University Cancer Institute, Singapore (NCIS), shared a post on X about an article he and Samuel Klempner authored:
“Targeting Claudin18.2 beyond monoclonal antibodies like zolbetixumab is arriving! In this article by Samuel Klempner and myself in Nature Medicine we discuss two promising Claudin18.2 targeting Antibody-Drug Conjugates.”
Title: Evolution of claudin18.2 therapies in gastroesophageal cancers
Authors: Samuel J. Klempner, Raghav Sundar
Read the Full Article in Nature Medicine.
Read more posts featuring Claudin18.2 on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Aug 23, 2025, 17:06
Aug 23, 2025, 16:59
Aug 23, 2025, 16:44
Aug 23, 2025, 16:36
Aug 23, 2025, 16:32
Aug 23, 2025, 16:30
Aug 23, 2025, 16:24